Mayo Clinic, which co-launched artificial intelligence-equipped drug developer Qrative with AI software provider Nference, has also contributed to its $8.3m series A round.
US-based drug developer Qrativ has launched with $8.3m of series A funding from investors including medical research group Mayo Clinic.
The series A round also featured private equity firm Matrix Partners, investment manager Matrix Capital Management and Andrew Badley, Qrativ’s co-founder and chief medical officer.
Mayo Clinic and artificial intelligence software provider Nference co-launched Qrativ, which will combine Nference’s AI-driven knowledge platform with Mayo Clinic’s medical data and expertise to discover new treatments for diseases not yet gaining the requisite…
